Daniel Peter Petrylak
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Pulmonary and Respiratory Medicine top 0.05%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Papers in
-
- Prostate Cancer Treatment and Research 140
- Prostate Cancer Diagnosis and Treatment 28
- Oncology 105
- Cancer Immunotherapy and Biomarkers 60
- Cancer Treatment and Pharmacology 12
- Co-authors
- Joaquim Bellmunt (28 shared papers)Mitchell C. Benson (20 shared papers)Maha Hussain (19 shared papers)Nicholas J. Vogelzang (25 shared papers)E. David Crawford (18 shared papers)Eric Jay Small (16 shared papers)Yohann Loriot (34 shared papers)Primo N. Lara (5 shared papers)
- Journals
- Annals of Oncology (54 papers)Journal of Clinical Oncology (39 papers)The Journal of Urology (26 papers)European Urology (14 papers)Cancer (14 papers)
- Partner nations
- United StatesFranceSpain
In The Last Decade
Daniel Peter Petrylak
345 papers receiving 33.1k citations
Daniel Peter Petrylak's Hit Papers
Peers
Comparison fields: 5 of 139
- Oncology 12.1k
- Pulmonary and Respiratory Medicine 11.5k
- Surgery 11.4k
- Cancer Research 3.3k
- Immunology 3.5k
Countries citing papers authored by Daniel Peter Petrylak
This map shows the geographic impact of Daniel Peter Petrylak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Peter Petrylak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Peter Petrylak more than expected).
Fields of papers citing papers by Daniel Peter Petrylak
This network shows the impact of papers produced by Daniel Peter Petrylak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Peter Petrylak. The network helps show where Daniel Peter Petrylak may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Peter Petrylak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 353 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer Hit paper breakdown → | 2004 | 3079 |
| 2 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2016 | 3043 |
| 3 | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma Hit paper breakdown → | 2017 | 2736 |
| 4 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Hit paper breakdown → | 2014 | 2018 |
| 5 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2016 | 1811 |
| 6 | Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma Hit paper breakdown → | 2020 | 1079 |
| 7 | Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group Hit paper breakdown → | 1999 | 880 |
| 8 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Hit paper breakdown → | 2021 | 876 |
| 9 | ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer Hit paper breakdown → | 2019 | 843 |
| 10 | Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy Hit paper breakdown → | 1996 | 539 |
| 11 | Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy Hit paper breakdown → | 2019 | 520 |
| 12 | TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors Hit paper breakdown → | 2021 | 432 |
| 13 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 400 |
| 14 | Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up Hit paper breakdown → | 2019 | 367 |
| 15 | Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer Hit paper breakdown → | 2016 | 363 |
| 16 | 2012 | 356 | |
| 17 | 2007 | 321 | |
| 18 | Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2021 | 319 |
| 19 | Chemotherapy for advanced renal-cell carcinoma: 1983-1993. | 1995 | 318 |
| 20 | 2009 | 286 |
About Daniel Peter Petrylak
Daniel Peter Petrylak is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 353 papers that have together received 33.9k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (140 papers), Bladder and Urothelial Cancer Treatments (130 papers), Cancer Immunotherapy and Biomarkers (60 papers), Urinary and Genital Oncology Studies (40 papers), Radiopharmaceutical Chemistry and Applications (31 papers), Prostate Cancer Diagnosis and Treatment (28 papers), Cancer, Lipids, and Metabolism (21 papers) and Cancer Treatment and Pharmacology (12 papers). The work is most often cited by research in Oncology (12.1k citations), Pulmonary and Respiratory Medicine (11.5k citations), Surgery (11.4k citations), Cancer Research (3.3k citations) and Immunology (3.5k citations). Daniel Peter Petrylak has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Joaquim Bellmunt, Mitchell C. Benson, Maha Hussain, Nicholas J. Vogelzang, E. David Crawford, Eric Jay Small, Yohann Loriot, Primo N. Lara, Catherine M. Tangen and Patrick A. Burch. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, The Journal of Urology, European Urology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.